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Abstract
Background and Aims: Data regarding the influence of dose and duration of aspirin use on risk of gastrointestinal bleeding
are conflicting.
Methods: We conducted a prospective cohort study of 32,989 men enrolled in the Health Professionals Follow-up Study
(HPFS) in 1994 who provided biennial aspirin data. We estimated relative risk of major gastrointestinal bleeding requiring
hospitalization or a blood transfusion.
Results: During 14 years of follow-up, 707 men reported an episode of major gastrointestinal bleeding over 377,231 person-
years. After adjusting for risk factors, regular aspirin use ($2 times/week) had a multivariate relative risk (RR) of
gastrointestinal bleeding of 1.32 (95% confidence interval [CI], 1.12–1.55) compared to non-regular use. The association was
particularly evident for upper gastrointestinal bleeding (multivariate RR, 1.49; 95% CI, 1.16–1.92). Compared to men who
denied any aspirin use, multivariate RRs of upper gastrointestinal bleeding were 1.05 (95% CI 0.71–1.52) for men who used
0.5–1.5 standard tablets/week, 1.31 (95% CI 0.88–1.95) for 2–5 aspirin/week, 1.63 (95% CI, 1.15–2.32) for 6–14 aspirin/week
and 2.40 (95% CI, 1.10–5.22) for .14 aspirin/week (Ptrend,0.001). The relative risk also appeared to be dose-dependent
among short-term users ,5 years; Ptrend,.001) and long-term users ($5 years; Ptrend=0.015). In contrast, after controlling for
dose, increasing duration of use did not appear to be associated with risk (Ptrend=0.749).
Conclusions: Regular aspirin use increases the risk of gastrointestinal bleeding, especially from the upper tract. However,
risk of bleeding appears to be more strongly related to dose than to duration of use. Risk of bleeding should be minimized
by using the lowest effective dose among short-term and long-term aspirin users.
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Introduction
Randomized trials have demonstrated that aspirin lowers the
risk of myocardial infarction among patients with prior cardio-
vascular disease as well as those with cardiovascular risk factors
[1,2,3]. Despite its therapeutic benefits, the limiting factor for
aspirin use has been its association with gastrointestinal toxicity,
particularly gastrointestinal bleeding. However, evidence regard-
ing the influence of aspirin dose on the risk of bleeding has been
conflicting as noted by a recent consensus statement from the
American College of Cardiology Foundation (ACCF) task force
[4]. Furthermore, pooled data in meta-analyses also showed
contradictory results [5,6,7].
Similarly, the effect of duration of aspirin use on risk of
gastrointestinal bleeding remains unclear. Some data suggest that
over time the gastrointestinal mucosa adapts to the adverse effects
of aspirin. This hypothesis has been supported by human studies
which have suggested that shorter duration of aspirin use was
associated with increased risk of gastrointestinal bleeding [8,9].
However, other studies show that bleeding risk is cumulative over
time [10]. These inconsistent results may be due to heterogeneous
study populations, small sample sizes, data on only a limited range
of doses, and relatively short duration of follow-up.
Thus, we examined the influence of aspirin use on the risk of
gastrointestinal bleeding among men enrolled in the Health
Professionals Follow-up study (HPFS) who provided detailed and
updated information on aspirin use over 20 year follow-up. This
cohort allows for a comprehensive examination of aspirin dose
based on prospectively collected data within the context of a range
of other lifestyle risk factors.
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Study Population
The HPFS is a prospective cohort of 51,529 U.S. male dentists,
optometrists, osteopaths, podiatrists, pharmacists and veterinari-
ans, who returned a health questionnaire in 1986. Subsequently,
biennial questionnaires were mailed to update information on diet,
aspirin use and medical diagnosis with a follow-up rate exceeding
90%. Return of the questionnaire was considered to imply
informed consent. The institutional review board at the Harvard
School of Public Health approved this study. We also obtained
written informed consent to review the medical records.
Assessment of Aspirin Use
In the 1986 questionnaire and every two years thereafter, we
inquired if men used aspirin, two or more time per week (‘‘e.g.
Anacin, bufferin, Alka-Seltzer’’), and other anti-inflammatory
medications (‘‘e.g. Motrin, Indocin, Naprosyn, Dolobid’’). Indi-
vidual non-steroidal anti-inflammatory drug (NSAID) types were
not collected. Beginning in 1992, we also asked men the average
frequency of intake and also number of aspirin tablets used (in
categories). Early in the study, most men used standard-dose
aspirin tablets of 325 mg [11]. However, to reflect overall secular
trends in consumption of low-dose, or baby aspirin, after 1992, we
asked participants to convert intake of four baby aspirin to one
adult tablet. Thus, dose category of 0.5 to 1.5 tablets/week was
equivalent to 81 milligrams/day (mg/day); 6–14 tablets/week was
equivalent to 325 mg/day. Beginning in 2000, questionnaires
specifically asked usual doses used by participants (50–99 mg,
100–249 mg, 250–349 mg and $350 mg). The reasons for aspirin
use were not assessed for the entire cohort, but a supplementary
questionnaire was sent in 1993 to a sample of 211 men who
reported aspirin use from 1986 to 1990 (88% response). The major
reasons for use were cardiovascular disease, 25.4%; to decrease
risk for cardiovascular disease, 58.4%; headaches, 25.4%; joint or
musculoskeletal pain, 33.0%; and other reasons, 7.0% [11].
Ascertainment of Outcome
In 2006 and 2008, we asked participants to report any episodes
of gastrointestinal bleeding which required hospitalization or
blood transfusion, a definition consistent with previous studies
[12]. Participants were also asked to provide the anatomic location
of the bleed (esophagus, stomach, duodenum, colon/rectum,
other, unknown) and the year of the bleed (in categories) over the
entire cohort study period. We classified cases into upper and
lower gastrointestinal bleeding; upper bleeding was defined as
bleeding originating from the esophagus, stomach, and duode-
num; lower bleeding was defined as bleeding arising from the
colon or rectum. As a validation, we verified accuracy of self-
reports by reviewing medical records among a subsample of 239
men who reported bleeding in which we archived blood specimens
in 1993–95 for a separate study of genetic risk factors for bleeding.
The baseline characteristics of the cohort of men who provided a
blood specimen were generally similar to men who did not. Two
study physicians (gastroenterologists) blinded to exposure infor-
mation, reviewed and extracted the data based from hospital
records, discharge summaries, endoscopy reports and pathology
reports if biopsy specimens were taken. We found the correlation
between self-reported date of diagnosis and confirmed date of
diagnosis was 0.87 (P-value ,0.001). The accuracy of the self-
reported classification of upper and lower gastrointestinal bleeding
was 93.3% (95% confidence interval [CI], 88.8%–96.4%). The
etiology of bleeding was validated based on the reports from
endoscopy, bleeding scans or angiograms when available. For
lower tract cases, diverticular bleeding was presumed if the active
diverticular bleeding site was not located and no other sources of
lower gastrointestinal bleeding was identified [13,14,15]. A third
reviewer was used to resolve discrepancies in assigning etiology of
bleeding between the two primary physician reviewers.
Statistical Analysis
At baseline, we included men who returned the 1994
questionnaire on aspirin use. We excluded those men with a prior
history of gastrointestinal bleeding, cancer or peptic ulcer disease.
We also excluded those cases of bleeding related to cancer or post-
polypectomy complications or without a known date of diagnosis.
After these exclusions, 32,989 men were eligible for analysis.
Person-time for each participant was calculated from the date of
return of the 1994 questionnaire to the date of their first
gastrointestinal bleed, death from any cause, or January 1, 2008,
whichever came first. We recognized that participants may have
varied their aspirin use over the follow-up time period. Thus, we
used time-varying covariates such that each participant contrib-
uted person-time according to the aspirin data they provided on
each biennial questionnaire. Consistent with previous analyses of
this cohort, we used cumulative average number of standard
aspirin tablets used prior to each two-year time period to estimate
dosage of aspirin use. We defined men who reported using aspirin
two or more times per week were defined as regular users where
those who reported less aspirin use were defined as non-regular
users [11,16,17]. We also grouped men according to previously
described number of standard (325 mg) aspirin tablets used per
week to estimate dosage of aspirin [17]. We examined the duration
of aspirin use by the number of years used according to response to
all biennial questionnaires prior to each 2-year follow-up interval.
We recalculated the duration of use each time there was a
cessation in regular aspirin use after the 1986 questionnaire.
We determined the incidence rates of gastrointestinal bleeding
for men in a specific category of aspirin use by dividing the
number of incident cases by the number of person-years. We
computed relative risk (RR) by dividing the incidence rate of
bleeding in one category divided by the incidence rate in the
reference category. To minimize any potential biases related to
either use or avoidance of aspirin, we censored participants after
the self-reported diagnosis of cancer during follow-up; these events
were not included as end points. We used Cox proportional
hazards modeling to control for multiple variables simultaneously
and to compute 95% confidence intervals (CI) [4,18,19,20,21]. We
used time-varying covariates in our model with the most updated
information for all covariates prior to each 2-year interval. In
additional analyses, we also adjusted for other clinical indications
for aspirin use and anticoagulants as time-varying covariates in our
multivariate model. The linear trend test across categories was
calculated by using the median value of each category and
modeling it as a continuous variable [22]. We evaluated
interactions by assessing the statistical significance of a cross-
product interaction term in the model. We used SAS version 9.1.3
(Cary, NC) for all analyses. All P values are two-sided, and a P
value less than 0.05 was considered significant.
Results
Among the 32,989 eligible men, we documented 707 gastroin-
testinal bleeding events over 377,231 person years. At baseline,
participants who used aspirin tended to be older, had higher body
mass indices, and were more likely to have diabetes, hypertension,
hypercholesterolemia, coronary artery disease, and osteoarthritis
compared to men who denied no aspirin use. Moreover, men who
Aspirin and Gastrointestinal Bleeding Risk in Men
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to be previous smokers (Table 1).
The overall absolute incidence in our cohort was 1.87 events per
1,000 person-years, within a similar range of prior studies [23].
The absolute risk of major gastrointestinal bleeding among regular
aspirin users ($2 times/week) was 2.31 events per 1000 person-
years compared to 1.38 events among nonregular users. We
observed a statistically significant higher risk for bleeding among
regular aspirin users compared with non-regular users even after
adjusting for other potential risk factors including body mass
index, physical activity, smoking, alcohol intake and concomitant
NSAID use (multivariate RR, 1.32; 95% CI, 1.12–1.55) (Table 2).
The effect appeared to be primarily related to upper gastrointes-
tinal bleeding (multivariate RR, 1.49; 95% CI, 1.16–1.92). For the
lower gastrointestinal tract, we found a non-significant association
between regular aspirin use and risk of bleeding (multivariate RR,
1.22; 95% CI 0.95–1.56).
Among the 239 cases for whom we reviewed complete medical
records, we found that the 53.1% of cases were bleeds which
originated from the upper gastrointestinal tract, 38.5% originated
from lower gastrointestinal tract, and 8.4% did not have a clearly
localized site of bleeding. The most common causes of upper
gastrointestinal bleeding were ulcers (64.0%), inflammation
(gastritis or duodenitis) (20%), Mallory-Weiss tear (4.0%),
arteriovenous malformations (2.4%), Dieulafoy’s lesions (1.6%),
and portal hypertension (1.6%). In the lower gastrointestinal tract,
the most common causes of bleeding were diverticular (66.7%),
inflammation (colitis) (18.0%), arteriovenous malformations
(3.9%), and ulcer (3.9%). An etiology was not identified in 4.8%
and 3.9% of bleeding arising from the upper tract and lower tract,
respectively.
We observed an increasing risk of gastrointestinal bleeding with
more frequent aspirin use even after adjustment for other bleeding
risk factors (Ptrend,.001) (Table 3). Compared to nonusers, men
who used aspirin most frequently ($6 days/week) had a
multivariate RR of 1.39 (95% CI, 1.14–1.69) for all gastrointes-
tinal bleeding and 1.56 (95% CI, 1.16–2.11) for upper gastroin-
testinal bleeding. Although we also observed a progressively
greater risk of lower gastrointestinal bleeding among men who
Table 1. Baseline characteristics of the study cohort in 1994.
Aspirin Tablets (325 mg) per week{
Characteristics
None
(n=14759)
0.5–1.5
(n=5854)
2–5
(n=5994)
6–14
(n=5819)
.14
(n=563)
Age, mean (SD), y 59.9 (9.3) 60.1 (9.1) 61.8 (9.2) 63.0 (9.1) 61.7 (8.8)
Body mass index, mean (SD), kg/m
2{ 25.8 (3.6) 25.9 (3.4) 26.0 (3.5) 26.3 (3.7) 26.6 (3.9)
Current NSAID use, No. (%)1 1721 (11.7) 669 (11.4) 841 (14.0) 815 (14.0) 105 (18.7)
Physical activity, mean (SD), MET/wk 36.5 (41.2) 36.7 (38.2) 38.2 (39.1) 36.2 (39.8) 33.8 (42.3)
Diabetes mellitus, No. (%) 707 (4.8) 272 (4.7) 296 (4.9) 457 (7.9) 40 (7.1)
Hypertension, No. (%) 3798 (25.7) 1745 (29.8) 2097 (35.0) 2484 (42.7) 230 (40.9)
Hypercholesterolemia, No. (%) 5229 (35.4) 2365 (40.4) 2672 (44.6) 3013 (51.8) 244 (43.3)
Coronary artery disease, No. (%) 406 (2.8) 319 (5.5) 479 (8.0) 1175 (20.2) 52 (9.2)
Osteoarthritis, No. (%) 2538 (17.2) 1054 (18.0) 1253 (20.9) 1408 (24.2) 259 (46.0)
Smoking status
Past, No. (%) 5865 (39.7) 2445 (41.8) 2654 (44.3) 2908 (50.0) 292 (51.9)
Current, No. (%) 787 (5.3) 314 (5.4) 284 (4.7) 304 (5.2) 29 (5.2)
Mean alcohol use, mean (SD), g/day 10.2 (14.5) 10.5 (13.7) 11.7 (14.5) 12.1 (15.6) 13.3 (18.4)
{One standard tablet is 325 mg of aspirin.
{Body mass index is weight in kilograms divided by the square of the height in meters.
1Current NSAID use is defined as regular intake of at least 2 times per week.
doi:10.1371/journal.pone.0015721.t001
Table 2. Relative risk of gastrointestinal bleeding according
to regular use of aspirin{.
Non-Regular
users Regular users P Value
All Cases*
Person-years 176496 200735
No of cases 244 463
Age-adjusted RR (95% CI) 1.0 1.36 (1.16–1.60) ,.001
Multivariate RR (95% CI){ 1.0 1.32 (1.12–1.55) 0.001
Upper GI Bleeding
Person-years 176496 200735
No of cases 99 204
Age-adjusted RR (95% CI) 1.0 1.53 (1.19–1.97) ,.001
Multivariate RR (95% CI){ 1.0 1.49 (1.16–1.92) 0.002
Lower GI Bleeding
Person-years 176496 200735
No of cases 110 193
Age-adjusted RR (95% CI) 1.0 1.26 (0.99–1.62) 0.063
Multivariate RR (95% CI){ 1.0 1.22 (0.95–1.56) 0.124
{Regular aspirin use is defined as consumption of $2 times per week. Non-
regular use is defined as consumption of ,2 times per week. Relative risks (RR)
are compared to non-regular users as reference group.
*Includes 101 individuals with unknown or unspecified location of GI bleeding.
{Multivariate RR model is adjusted for age, NSAID use (yes or no), smoking
status (never, past, current), body mass index (,21. 21–22.9, 23–24.9, 25–29.9,
$30 kg/m
2), exercise (,1.7, 1.7–4.5, 4.6–10.5, 10.6–22.0, $22.1 mets/week),
alcohol (0, 0.1–4.9, 5–14.9, $15 g/day).
doi:10.1371/journal.pone.0015721.t002
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was attenuated after adjusting for other bleeding risk factors
(Ptrend=0.055).
Since men who used aspirin more frequently were more likely to
have used the drug for longer periods, we examined the influence
of duration of aspirin use with risk (Table 4). Compared to men
who denied any aspirin use, participants who reported greater
than 10 years of aspirin use had an age-adjusted RR of 1.26 (95%
CI, 0.99–1.62; Ptrend=0.050) for gastrointestinal bleeding. How-
ever, after adjusting for dose of aspirin as well as other potential
confounders, the effect was no longer significant (Ptrend=0.749).
For upper gastrointestinal bleeding, we found a similar relation-
ship between duration of use and risk of bleeding (Ptrend=0.012).
However, after we controlled for the aspirin dose, we again found
that the association was no longer evident (Ptrend=0.641). No
significant association was seen between duration of use and lower
gastrointestinal bleeding.
We found that gastrointestinal bleeding risk progressively
increased with higher doses (Ptrend,.001) (Table 5). In particular,
men who used dose equivalent to 325 mg/day (6–14 tablets/week)
had higher risk of upper gastrointestinal bleeding (multivariate
RR, 1.63; 95% CI, 1.15–2.32) than men who used dose equivalent
to 81 mg/day (0.5 to 1.5 tablets/week) (multivariate RR 1.05;
95% CI, 0.71–1.54). We also observed that the dose-response
effect remained significant for all gastrointestinal bleeding
(Ptrend,.001) and upper gastrointestinal bleeding (Ptrend,.001) even
after controlling for duration of use. For lower tract bleeding, we
did not find a significant relationship between aspirin dose and risk
of bleeding. Specifically, we found that dose category equivalent to
81 mg/day had a similar risk in lower gastrointestinal bleeding
(multivariate RR, 1.24; 95% CI, 0.87–1.76) compared to dose
category equivalent to 325 mg/day (multivariate RR, 1.31; 95%
CI, 0.92–1.86). We also performed analysis beginning from 2000
when specific doses were first asked (Table 6). Individuals who
took 50–99 mg or baby aspirin equivalent had a multivariate RR
of 1.21 (95% CI, 0.94–1.57); 250–349 mg or standard aspirin
equivalent had a multivariate RR of 1.69 (95% CI, 1.26–2.27).
These results did not differ appreciably when restricted to only
daily users (multivariate RR, 1.17; 95% CI, 0.89–1.53 for 81 mg
equivalent and multivariate RR, 1.67; 95% CI, 1.20–2.33 for
325 mg equivalent).
We also examined the effect of dose among intermittent users
(1–5 days/week) and daily users ($6 days/week) of aspirin
(Table 7). In both groups, the influence of aspirin on
gastrointestinal bleeding remained dose-dependent (Ptrend=0.005
among intermittent users and Ptrend=0.007 among daily users). We
also found a strong dose-response relationship among both short-
term users (,5 years use) (Ptrend,.001) and long-term users ($5
years) (Ptrend=0.015). To assess if duration or frequency of aspirin
use significantly modified the association between aspirin dose and
bleeding risk, we examined cross-product interaction terms. We
did not observe any statistically significant interaction between
aspirin dose and either frequency (Pinteraction=0.255) or duration
(Pinteraction=0.202).
In 1994, the baseline prevalence of cardiovascular disease was
low with 7.4% of the men having a history of coronary heart
disease, 0.8% prior stroke and 0.1% prior atrial fibrillation. In
addition, 1.7% had a history of venous thromboembolism (deep
vein thrombosis or pulmonary embolism). Through 2008, 13.0%
of men had a history of coronary heart disease (of whom 63.8%
reported having had a coronary angiography), 1.8% stroke, 0.6%
atrial fibrillation, and 3.4% venous thromboembolism. We
Table 3. Relative risk of gastrointestinal bleeding according to frequency of aspirin use{.
Days per week of use
None ,2 2–3 4–5 $6 P trend**
All Cases*
Person-years 117552 58944 32742 24607 143386
No of cases 163 81 42 52 369
Age-adjusted RR (95% CI) 1.0 1.02 (0.78–1.34) 0.91 (0.64–1.28) 1.51 (1.09–2.07) 1.46 (1.20–1.77) ,.001
Multivariate RR (95% CI){ 1.0 1.02 (0.78–1.34) 0.90 (0.64–1.28) 1.51 (1.09–2.07) 1.39 (1.14–1.69) ,.001
Upper GI Bleeding
Person-years 117552 58944 32742 24607 143386
No of cases 66 33 22 21 161
Age-adjusted RR (95% CI) 1.0 1.02 (0.67–1.56) 1.17 (0.72–1.91) 1.55 (0.94–2.56) 1.63 (1.21–2.21) ,.001
Multivariate RR (95% CI){ 1.0 1.01 (0.66–1.54) 1.17 (0.72–1.91) 1.54 (0.93–2.55) 1.56 (1.16–2.11) ,.001
Lower GI Bleeding
Person-years 117552 58944 32742 24607 143386
No of cases 74 36 18 22 153
Age-adjusted RR (95% CI) 1.0 1.01 (0.67–1.51) 0.87 (0.52–1.46) 1.34 (0.83–2.18) 1.34 (1.00–1.79) 0.021
Multivariate RR (95% CI){ 1.0 0.99 (0.66–1.48) 0.85 (0.51–1.44) 1.33 (0.82–2.17) 1.27 (0.94–1.70) 0.055
{Relative risks (RR) are compared to those without any aspirin use as reference group.
*Includes 101 individuals with unknown or unspecified location of GI bleeding
**P trend calculated using median aspirin frequency of each category as continuous variable
{Multivariate RR model is adjusted for age, NSAID use (yes or no), smoking status (never, past, current), body mass index (,21. 21–22.9, 23–24.9, 25–29.9, $30 kg/m
2),
exercise (,1.7, 1.7–4.5, 4.6–10.5, 10.6–22.0, $22.1 mets/week), alcohol (0, 0.1–4.9, 5–14.9, $15 g/day).
Multivariate RR model is adjusted for aforementioned variables as well as aspirin dose (continuous use in tablets per week).
doi:10.1371/journal.pone.0015721.t003
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risk of bleeding according to aspirin use. However, additionally
adjusting for the diagnoses of coronary heart disease, atrial
fibrillation, stroke and venous thromboembolism did not materi-
ally alter our risk estimates (multivariate RR, 1.41; 95% CI, 1.15–
1.72). Furthermore, we also considered the influence of warfarin
use on gastrointestinal bleeding risk in our cohort. Data on use of
warfarin was routinely collected beginning in 1996. In 1996, 2.6%
of participants were using warfarin regularly; while in 2004, 5.1%
of participants used warfarin. After restricting the analysis to
follow-up after 1996, additional adjustment for use of warfarin did
not materially alter the risk of bleeding among regular aspirin users
(multivariate RR, 1.44; 95% CI, 1.16–1.80).
Similarly, we considered the possibility that concurrent use of
proton pump inhibitors or histamine-2 antagonists may influence
our results. After additional adjustment for use of proton pump
inhibitors and histamine-2 antagonists, the risk of bleeding
remained significant (multivariate RR, 1.38; 95% CI, 1.13–1.69).
Finally, we evaluated possible differences in the influence of
aspirin according to strata of clinical characteristics. There were
no significant differences in the effect of regular aspirin use in the
strata defined by age, body mass index, NSAID use, smoking or
alcohol use (Figure 1).
Discussion
In this prospective, population-based cohort of men, we found
that long-term, regular aspirin use ($2 times per week) was
associated with an increased risk of gastrointestinal bleeding.
Moreover, the risk of gastrointestinal bleeding increased with
higher doses of aspirin with the greatest risk observed among men
who used .14 standard (325-mg) tablets per week. This effect was
primarily evident for bleeding originating from the upper
gastrointestinal tract. Notably, we observed this dose-response
relationship among intermittent users (1–5 days/week) and daily
users ($6 days/week), and among short-term (,5 years) and long-
term ($5 years) users. In contrast, the duration of aspirin use did
not appear to be significantly associated with gastrointestinal
bleeding after controlling for dose. Furthermore, dose category
equivalent to 325 mg/day (6–14 tablets/week) was associated with
a higher risk of upper gastrointestinal bleeding (multivariate RR,
1.63; 95% CI 1.15–2.32) compared to dose category equivalent to
81 mg/day (0.5 to 1.5 tablets/week) (multivariate RR, 1.05; 95%
CI, 0.71–1.54).
Data from previous controlled trials, case-controlled studies,
and meta-analyses generally support our findings that aspirin use is
associated with increased risk of major gastrointestinal bleeding
[1,2,3,5,6,7,12,24,25,26,27,28,29,30]. However, previous results
from most controlled trials were based on individuals with
cardiovascular disease, limiting their generalizability. In addition,
case-control studies may overestimate risk due to a retrospective
assessment of aspirin use or the selection of a non-representative
control population. Many previous studies also have relatively
short follow-up time, examine only a few aspirin doses, or have
limited data on a range of potential confounding factors.
Several lines of evidence support the dose-dependent effect of
aspirin we observed. Animal models show that size of aspirin-
mediated gastric lesions are dose-dependent [31]. In addition,
Table 4. Relative risk of gastrointestinal bleeding according to duration of regular aspirin use{.
Duration of Continuous Use (years)
None 1–5 6–10 .10 P trend**
All Cases*
Person-years 176496 103931 56853 39950
No of cases 244 241 130 92
Age-adjusted RR (95% CI) 1.0 1.40 (1.16–1.68) 1.38 (1.10–1.72) 1.26 (0.99–1.62) 0.050
Multivariate RR (95% CI){ 1.0 1.35 (1.12–1.62) 1.36 (1.09–1.70) 1.18 (0.92–1.52) 0.131
Multivariate RR + Dose (95% CI)1 1.0 1.19 (0.95–1.48) 1.18 (0.91–1.53) 1.01 (0.75–1.35) 0.749
Upper GI Bleeding
Person-years 176496 103931 56853 39950
No of cases 99 101 61 42
Age-adjusted RR (95% CI) 1.0 1.47 (1.10–1.96) 1.68 (1.20–2.34) 1.50 (1.03–2.18) 0.012
Multivariate RR (95% CI){ 1.0 1.44 (1.07–1.91) 1.67 (1.19–2.33) 1.41 (0.97–2.06) 0.027
Multivariate RR + Dose (95% CI)1 1.0 1.18 (0.84–1.66) 1.33 (0.90–1.96) 1.11 (0.71–1.71) 0.641
Lower GI Bleeding
Person-years 176496 103931 56853 39950
No of cases 110 102 49 42
Age-adjusted RR (95% CI) 1.0 1.33 (1.00–1.75) 1.15 (0.81–1.62) 1.27 (0.88–1.83) 0.345
Multivariate RR (95% CI){ 1.0 1.27 (0.96–1.69) 1.12 (0.79–1.59) 1.19 (0.82–1.72) 0.522
Multivariate RR + Dose (95% CI)1 1.0 1.20 (0.86–1.68) 1.05 (0.70–1.57) 1.10 (0.71–1.70) 0.932
{Relative risks (RR) are compared to those without any continuous aspirin use as reference group.
*Includes 101 individuals with unknown or unspecified location of GI bleeding.
**P trend calculated using median aspirin dose of each category as continuous variable.
{Multivariate RR model is adjusted for age, NSAID use (yes or no), smoking status (never, past, current), body mass index (,21. 21–22.9, 23–24.9, 25–29.9, $30 kg/m
2),
exercise (,1.7, 1.7–4.5, 4.6–10.5, 10.6–22.0, $22.1 mets/week), alcohol (0, 0.1–4.9, 5–14.9, $15 g/day).
1Multivariate RR model is adjusted for aforementioned variables as well as aspirin dose (continuous use in tablets per week).
doi:10.1371/journal.pone.0015721.t004
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mucosal prostaglandin synthesis [32,33]. A recent meta-analysis of
clinical trials showed that rate of major bleeding events increased
with higher doses of aspirin. Patients taking .200 mg aspirin/day
had 2.69% chance of having a major gastrointestinal bleeding
event compared to 0.97% in patients taking ,100 mg/day
(P=0.001) [5]. Another study showed that daily doses of 75 mg,
150 mg and 300 mg of aspirin were associated with odd ratios of
2.3 (95% CI, 1.2–4.4), 3.2 (95% CI 1.7–6.5) and 3.9 (95% CI 2.5
to 6.3), respectively [30].
With over 20 years of follow-up, our present study was uniquely
able to examine the influence of duration of aspirin use on
bleeding risk. Although increasing duration of use was associated
with greater risk of bleeding, this effect was no longer evident after
accounting for the higher dose typically used by long-term users.
These findings are supported by experimental data that have
demonstrated that gastric mucosa may adapt to the ulcerogenic
properties of aspirin after prolonged exposure [34,35,36]. In
human studies, several clinical trials have also suggested that
aspirin use is associated primarily with gastrointestinal complica-
tions early in treatment, supporting the potential for gastrointes-
tinal mucosal adaptation [26,30,37,38,39].
We did evaluate the effects of other medications known to
potentially influence bleeding risk, such as proton pump inhibitors
andhistamine-2antagonists.Severalstudieshaveshownthatproton
pump inhibitors can reduce ulcer formation, upper gastrointestinal
bleeding and need for surgery [40,41,42,43,44,45]. Similarly,
Table 5. Relative risk of gastrointestinal bleeding according to dose of aspirin use{.
Aspirin Tablets (325 mg) per week
None 0.5–1.5 2–5 6–14 .14 P trend**
All Cases*
Person-years 117552 76515 65668 111768 5728
No of cases 163 137 91 301 15
Age-adjusted RR (95% CI) 1.0 1.21 (0.96–1.53) 1.00 (0.77–1.30) 1.49 (1.22–1.82) 1.77 (1.03–3.03) ,.001
Multivariate RR (95% CI){ 1.0 1.20 (0.95–1.51) 0.99 (0.76–1.29) 1.42 (1.16–1.74) 1.70 (0.99–2.90) ,.001
Multivariate RR + Duration (95% CI)1 1.0 1.22 (0.96–1.54) 1.02 (0.78–1.34) 1.49 (1.18–1.87) 1.80 (1.03–3.13) ,.001
Upper GI Bleeding
Person-years 117552 76515 65668 111768 5728
No of cases 66 48 47 134 8
Age-adjusted RR (95% CI) 1.0 1.07 (0.73–1.56) 1.30 (0.89–1.90) 1.68 (1.24–2.29) 2.41 (1.14–5.09) ,.001
Multivariate RR (95% CI){ 1.0 1.04 (0.71–1.52) 1.30 (0.89–1.91) 1.61 (1.18–2.20) 2.36 (1.11–5.00) ,.001
Multivariate RR + Duration (95% CI)1 1.0 1.05 (0.71–1.54) 1.31 (0.88–1.95) 1.63 (1.15–2.32) 2.40 (1.10–5.22) ,.001
Lower GI Bleeding
Person-years 117552 76515 65668 111768 5728
No of cases 74 64 35 125 5
Age-adjusted RR (95% CI) 1.0 1.26 (0.89–1.77) 0.83 (0.55–1.25) 1.38 (1.02–1.87) 1.27 (0.51–3.17) 0.050
Multivariate RR (95% CI){ 1.0 1.24 (0.88–1.74) 0.81 (0.54–1.23) 1.30 (0.96–1.77) 1.18 (0.47–2.94) 0.128
Multivariate RR + Duration (95% CI)1 1.0 1.24 (0.87–1.76) 0.82 (0.53–1.25) 1.31 (0.92–1.86) 1.19 (0.46–3.04) 0.164
{Relative risks (RR) are compared to non-users as reference group.
*Includes 101 individuals with unknown or unspecified location of GI bleeding.
**P trend calculated using median aspirin dose of each category as continuous variable.
{Multivariate RR model is adjusted for age, NSAID use (yes or no), smoking status (never, past, current), body mass index (,21. 21–22.9, 23–24.9, 25–29.9, $30 kg/m
2),
exercise (,1.7, 1.7–4.5, 4.6–10.5, 10.6–22.0, $22.1 mets/week), alcohol (0, 0.1–4.9, 5–14.9, $15 g/day).
1Multivariate RR model is also adjusted for aspirin duration (continuous use in years).
11Multivariate RR model is also adjusted for aspirin frequency (median aspirin frequency of each category as continuous variable).
doi:10.1371/journal.pone.0015721.t005
Table 6. Aspirin dose and risk of gastrointestinal bleeding
(2000–08).
Aspirin Dose
None 81 mg{ 325 mg1
All Cases*
Person-years 71094 41190 21256
No of cases 139 115 71
Age-adjusted 1.0 1.24 (0.96–1.60) 1.73 (1.29–2.32)
Multivariate-adjusted{ 1.0 1.21 (0.94–1.57) 1.69 (1.26–2.27)
Daily Users
Person-years 71094 34663 14988
No of cases 139 94 52
Age-adjusted 1.0 1.18 (0.90–1.54) 1.69 (1.22–2.35)
Multivariate-adjusted{ 1.0 1.17 (0.89–1.53) 1.67 (1.20–2.33)
{Individuals reported taking 50–99 mg of aspirin.
1Individuals reported taking 250–349 mg of aspirin.
*Includes 49 bleeding cases which were unspecified. Includes non-daily and
daily users.
{Multivariate RR model is adjusted for age, NSAID use (yes or no), smoking
status (never, past, current), body mass index (,21. 21–22.9, 23–24.9, 25–29.9,
$30), exercise (,1.7, 1.7–4.5, 4.6–10.5, 10.6–22.0, $22.1 mets/week), alcohol
(0, 0.1–4.9, 5–14.9, $15 g/day).
doi:10.1371/journal.pone.0015721.t006
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prevent duodenal ulcers and reduce risk of upper gastrointestinal
bleeding [42,46,47]. In our study, concurrent use of these
medications did not appear to significantly influence the risk of
bleeding among regular aspirin users. However, these findings
should be interpreted with caution given the relatively small
proportion of the cohort used these medications over follow-up
compared to aspirin users. For example, in 2004, 14.0% and 5.6%
were regular users of proton pump inhibitors and histamine-2
antagonists, respectively. Moreover, although proton pump
inhibitors and histamine-2 antagonists may reduce risk of
aspirin-related bleeding among individuals with preexisting ulcer
disease, it remains unclear if these drugs specifically influence risk
of initial bleeding or if chronic use of these medications can
influence long-term risk [48]. Further studies should examine the
potential differential effect of proton pump inhibitors and
histamine-2 antagonists on bleeding risk among chronic aspirin
users.
Although previous studies have demonstrated an association
between aspirin and risk of gastrointestinal bleeding [5,6,7], our
study differs in several important ways. First, we collected detailed,
updated information on aspirin use at a wider range of doses and
over longer follow-up than would be feasible to examine in most
other studies. Second, we prospectively collected aspirin data prior
to diagnosis. Thus, any recall bias would be minimized and likely
have attenuated true associations. Third, we were able to estimate
several distinct parameters of aspirin use such as dose, duration
and frequency of use, making our findings less prone to internal
confounding due to correlations among these variables (eg use at
higher doses may reflect more consistent use). Fourth, since our
participants were all health professionals, the accuracy of self-
reported aspirin use is likely to be high and reflect actual
consumption. Finally, we used time-varying, biennially updated
data on aspirin use and other risk factors in our analysis which
minimizes any residual confounding related to changes in risk
factors over time.
Our study also has limitations that deserve comment. First,
aspirin use was self-selected which may affect the reliability of our
results. However, our findings are consistent with widely accepted
biological mechanisms in experimental models and the results of
prior clinical trials [5,6,7]. Furthermore, adjustment for a wide
range of potential factors had minimal influence on our findings,
suggesting little potential for residual or uncontrolled confounding.
Second, assessment of gastrointestinal bleeding did not begin until
2006 which may have led to underascertainment of cases.
However, with a high response rate (.90%) and low overall
incidence rate of gastrointestinal bleeding, the number of missed
cases are likely to be low. Third, since we did not confirm the exact
date and cause of each case of gastrointestinal bleeding,
misclassification bias is possible. However, among the subset of
men for whom we retrieved medical records, we found the self-
reported date of diagnosis and location of bleed to be highly
Table 7. Relative risk of gastrointestinal bleeding according to dose of aspirin use{.
Aspirin Tablets (325 mg) per week
None 0.5–1.5 2–5 6–14 .14 P trend**
Intermittent Users (1–5 days/week)
Person-years 117552 53183 47938 14254 918
No of cases 163 72 61 39 3
Age-adjusted RR (95% CI) 1.0 1.03 (0.77–1.36) 0.95 (0.70–1.28) 1.77 (1.23–2.54) 2.08 (0.63–6.86) 0.003
Multivariate RR (95% CI){ 1.0 1.02 (0.77–1.36) 0.96 (0.71–1.30) 1.67 (1.16–2.42) 2.16 (0.66–7.06) 0.005
Daily Users ($6 days/week)
Person-years 117552 23332 17729 97514 4811
No of cases 163 65 30 262 12
Age-adjusted RR (95% CI) 1.0 1.57 (1.16–2.12) 1.17 (0.78–1.74) 1.47 (1.19–1.82) 1.67 (0.92–3.03) 0.002
Multivariate RR (95% CI){ 1.0 1.53 (1.13–2.07) 1.13 (0.76–1.69) 1.42 (1.15–1.76) 1.58 (0.87–2.87) 0.007
Short-Term Users (,5 years)1
Person-years 117552 63007 44449 53167 2250
No of cases 163 104 57 154 7
Age-adjusted RR (95% CI) 1.0 1.17 (0.91–1.50) 0.95 (0.70–1.30) 1.59 (1.26–2.01) 2.33 (1.08–5.06) ,.001
Multivariate RR (95% CI){ 1.0 1.15 (0.89–1.48) 0.95 (0.70–1.29) 1.52 (1.20–1.93) 2.16 (0.99–4.70) ,.001
Long-Term Users ($5 years)1
Person-years 117552 13508 21219 58601 3479
No of cases 163 33 34 147 8
Age-adjusted RR (95% CI) 1.0 1.45 (0.98–2.14) 1.12 (0.77–1.64) 1.43 (1.13–1.82) 1.47 (0.71–3.04) 0.008
Multivariate RR (95% CI){ 1.0 1.42 (0.96–2.09) 1.14 (0.78–1.66) 1.39 (1.09–1.78) 1.49 (0.72–3.09) 0.015
{Relative risks (RR) are compared to non-users as reference group.
{Multivariate RR model is adjusted for age, NSAID use (yes or no), smoking status (never, past, current), body mass index (,21. 21–22.9, 23–24.9, 25–29.9, $30 kg/m
2),
exercise (,1.7, 1.7–4.5, 4.6–10.5, 10.6–22.0, $22.1 mets/week), alcohol (0, 0.1–4.9, 5–14.9, $15 g/day).
**P trend calculated using median aspirin dose of each category as continuous variable.
1Reference group for both short-term and long-term analyses are individuals who reported no use of aspirin (0 years and 0 tablets/week).
doi:10.1371/journal.pone.0015721.t007
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of upper gastrointestinal bleeding cases were due to ulcer disease
or gastritis/duodenitis, while causes of lower gastrointestinal
bleeding were attributed to diverticular disease or colitis. These
findings are consistent with other studies of major bleeding
[38,49]. Fourth, our study population consisted of male health
professionals, which may limit the generalizability to other
population. However, there is little biological reason to expect
that differences in the association of aspirin with bleeding would
differ by occupation. Moreover, we conducted a similar analysis
using the Nurses Health Study, a prospective cohort of women and
found consistent results [50]. Finally, we did not specifically
inquire about the use of clopidogrel through 2006. However,
clopidogrel was not widely used in the U.S. population over the
time period of the study (prior to 2008). In our 2008 biennial
questionnaire, only 3.7% of individuals reported using this
medication. Thus, it is unlikely that concomitant use of clopidogrel
over the time period of follow-up could account for our findings.
Although the results of our study are not as definitive as a
randomized controlled trial, we believe that such a study would
not likely be ethical or feasible since the low incidence of events
would require a large number of participants, particularly if
multiple aspirin doses are examined. Moreover, since aspirin use
for disease prevention requires chronic intake over many years, the
prolonged follow-up would be prohibitive.
In conclusion, our findings showed that regular aspirin use is
associated with higher risk of gastrointestinal bleeding, especially
from the upper tract. Specifically, we found doses equivalent to
325 mg/day was associated with a higher risk of upper
gastrointestinal bleeding compared to doses equivalent to
81 mg/day. Moreover, our study suggests that this effect is more
strongly related to dose than to duration or frequency of use.
These data suggests that minimization of bleeding risk should
focus on using the lowest effective dose for both short-term and
long-term users.
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Figure 1. Multivariate-adjusted stratified analyses of gastrointestinal bleeding risk according to aspirin use. Multivariate hazard ratios
are adjusted for age (years), NSAID use (yes or no), smoking status (never, past, current), body mass index (,21, 21–22.9, 23–24.9, 25–29.9, $30 kg/m
2),
physicalactivity (,1.7,1.7–4.5, 4.6–10.5,10.6–22.0,$22.1 mets/week),alcohol (0,0.1–4.9,5–14, $15 g/day). For each stratifiedanalysis, thestratification
variable was omitted from the model.
doi:10.1371/journal.pone.0015721.g001
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